Antidepressant activity of phosphodiesterase 3 inhibitor: Cilostazol

International Journal of Pharmaceutical and Clinical Research

Volumn 3, Issue 3, 2011, Pages 52-54

  Bhatt, P A ^a   Patel, D S ^b   Anand, I S ^b   Shah, U G ^c   Patel, S B ^d  

^a L M COLLEGE OF PHARMACY   (India)

^b Shri Sarvajanik Pharmacy College   (India)

^c Interventional Cardiologist   (India)

^d Care Institute of Medical Sciences   (India)

Author keywords

Antidepressant activity; Cilostazol; MADRS; PDE3 inhibitor

Indexed keywords

CILOSTAZOL;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROPROTECTION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PROSPECTIVE STUDY; REMISSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION;

EID: 84857956402     PISSN: None     EISSN: 09751556     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Stahl SM. Essential psychopharmacology. Neuroscientific basis and practical: applications. Cambridge University Press; 1988.
2. Rechelson E. Pharmacology of antidepressants. Mayo clin Proc. 1990; 65:1227-36.
3. Rechelson E. Pharmacology of antidepressants. Mayo clin Proc. 2001; 76: 516-27.
4. th ed. Medical publishers Pvt. Ltd., New Delhi, India, 2005, 168-72.
5. Lett H, Ali S, Whooley M. Depression and Cardiac Function in Patients with Stable Coronary Heart Disease: Findings from the Heart and Soul Study. Psychosomatic Medicine. 2008; 70: 444-449.
6. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985; 35: 1144-1149.
7. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998; 98: 678-686.
8. Liu Y, Shakur Y, Yoshitake M, Kambayashi J. Cilostazol (Pletal®): A Dual Inhibitor of Cyclic Nucleotide Phosphodiesterase Type 3 and Adenosine Uptake. Cardiovascular Drug Rev. 2001; 19(4): 369-386.
9. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, et al. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D Phosphodiesterase enzyme. Neuropsychopharmacology. 2002; 27: 587-595.
10. Maxwell CR, Kanes SJ, Abel T, Siegel SJ. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience. 2004; 129: 101-107.
11. Campbell E, Edwards T. Zaprinast consolidates long-term memory when administered to neonate chicks trained using a weakly reinforced single trial passive avoidance task. Behav. Brain Res. 2006. 169: 181-185.
12. Itoh T, Tokumura M, Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur. J. Pharmacol. 2004. 498: 135-142.
13. Menniti FS, Chappie TA, Humphrey JM, Schmidt, CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr. Opin. Investig. Drugs. 2007; 8: 54-59.
14. Nishimura K, Ishigooka J, Imamura Y, Ihara S. Cilostazol, a cAMP Phosphodiesterase 3 Inhibitor in the Treatment of Poststroke Depression. J Neuropsychiatry Clin Neurosci. 2007; 19: 471-472.
15. Mulder RT, Joyce PR, Frampton C. Relationships among measures of treatment outcome in depressed patients. J Affect Disord. 2003; 76(1-3): 127-135.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979; 134: 382-389.
17. Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP. A comparison of depression rating scales. Br. J. Psychiatry. 1982; 141: 45-49.
18. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, Woo A, Trivedi MH. The Montgomery Asberg and the Hamilton ratings of depression: A comparison of measures. Eur. Neuropsychopharmacol. 2006; 16(8): 601-611.
19. Rocca P, Fonzo V, Ravizza L, Rocca G, Scotta M, Zanalda E, Bogetto F. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord. 2002; 70(3): 313-317.
20. Thase ME, Trivedi MH, Nelson JC, Fava M, Swanink R, Tran QV, Pikalov A, Yang H, Carlson BX, Marcus RN, Berman RM. Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Analysis of 2 Studies. Prim Care Companion J Clin Psychiatry. 2008; 10(6): 440-447.
21. Jain S, Carmody T, Trivedi MH, Hughes C, Bernstein I, Morris DW, Emslie GJ, Rush AJ. A Psychometric Evaluation of the CDRS and MADRS in Assessing Depressive Symptoms in Children." J Am Acad Child Adolesc Psychiatry. 2007; 46(9): 1204-1212.
22. Halene TB, Siegel SJ, "PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia?" Drug Discovery Today. 2007; 12(19/20): 870-878.
23. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics." Psychopharmacol. Bull. 2001; 35: 5-49.
24. Perez J, Tardito D. Implications of the cAMP signaling pathway in psychiatric disorders: a systematic review of the evidence. CNS Spectr. 2001; 6: 294-305.
25. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 2004; 25: 158-163.
26. Janet B, Williams W, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA). The Br. J. Psychiatry. 2008; 192: 52-58.